LLY241220P850000
- 74.10
- +4.50+6.47%
Eli Lilly and Co Newsroom
Eli Lilly and Co's potential blockbuster new drug donanemab has been approved for sale in China! It is used for treating Alzheimer's disease.
On December 18, Eli Lilly and Co (LLY.US) just announced that its Class 1 new drug donanemab injection application has been approved by the National Medical Products Administration of China (NMPA).
Merck-Hansoh Deal for Oral GLP-1 Hurts Obesity Drug Developers
Least Shorted S&P 500 Stocks in November
Lilly Rival Gets FDA Okay for Phase 2 Study of Obesity Drug
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs. -- Barrons.com
Merck Enters Obesity Drug Race in Pact With Chinese Pharma Hansoh
FDA Clears Gan & Lee's Investigational New Drug Application To Conduct Phase 2 Head-To-Head Trial Of Bi-Weekly Bofanglutide, For Chronic Weight Management Indication Against Eli Lilly's Tirzepatide
Express News | The first Alzheimer's disease treatment that requires an injection once a month has arrived.
Eli Lilly's Kisunla Approved for Early Alzheimer's Patients in China
Eli Lilly Secures Chinese Approval for Early Symptomatic Alzheimer's Disease Medicine
Express News | Eli Lilly and Co's Alzheimer's disease therapy, Donanemab injection, has been approved in China.
Express News | Eli Lilly and Co: Kisunla continues to show substantial effectiveness in treating patients with early symptoms of Alzheimer's disease.
Peering Into Eli Lilly's Recent Short Interest
NVS Vs. LLY: Which Stock Should Value Investors Buy Now?
Behind the Scenes of Eli Lilly's Latest Options Trends
The Stock Market Is One Big Contradiction Right -2-
Lilly Endowment Donates $10 Million for American Red Cross Service to the Armed Forces
Cash / Money Market reserves may reach 80 billion USD! Novo-Nordisk A/S (NVO.US) and Eli Lilly and Co (LLY.US) are expected to initiate a merger and acquisition frenzy.
Novo-Nordisk A/S and Eli Lilly and Co (LLY.US), two pharmaceutical giants that have achieved great success in the field of weight loss drugs, may trigger a wave of large-scale mergers and acquisitions in 2025.
Lilly's Kisunla (Donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Lilly and EVA Pharma Announce Regulatory Approval and Release of Locally Manufactured Insulin in Egypt